Minimally Invasive Rheumatic Mitral Valve Surgery
Early Outcome of Minimally Invasive Rheumatic Mitral Valve Surgery Through Periareolar Versus Submamary Approach
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: mohammed R hamed, becholar in general surgery
- Phone Number: 01024631721
- Email: x_spiders123@yahoo.com
Study Contact Backup
- Name: Ahmed Elminshawy, MD in cardiothoracic surgery
- Phone Number: 01112743943
- Email: aelminshawy@aun.edu.eg
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinical diagnosis of rheumatic mitral valve
- Patient undergoing minimal invasive rheumatic mitral valve surgery
- Patient is willing to comply with all follow-up visits.
- Willing and able to provide written informed consent and comply with study requirements
Exclusion Criteria:
- Ischemic heart disease
- Patients need another valve replacement
- Redo mitral valve replacement
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
group A
periareolar approach
|
First, venous and arterial access was established.
Incision establishment: A 4 to 6 cm incision was opened in the chest anterolaterally to the right of the fourth intercostal space (in submamarry vs. peri areolar approach ).
The thoracoscope was inserted.
Bypass started, and Chitwood occlusion forceps were inserted to block the ascending aorta, purse-string suturing of the cardioplegia cannula and antegradecardioplegia fluid was performed, the interatrial groove was freed, the left atrial incision was made.
Removal of the damaged mitral valve mostly by endoscopic surgical instruments (not usually there is a chance for repair), and the mitral valve was sutured intermittently.
After examination of the valve location and the opening and closing performance of the valve leaf, the left atrial incision was sutured continuously by prolene 4/0.
Weaning from bypass start
|
|
group B
submamary approach
|
First, venous and arterial access was established.
Incision establishment: A 4 to 6 cm incision was opened in the chest anterolaterally to the right of the fourth intercostal space (in submamarry vs. peri areolar approach ).
The thoracoscope was inserted.
Bypass started, and Chitwood occlusion forceps were inserted to block the ascending aorta, purse-string suturing of the cardioplegia cannula and antegradecardioplegia fluid was performed, the interatrial groove was freed, the left atrial incision was made.
Removal of the damaged mitral valve mostly by endoscopic surgical instruments (not usually there is a chance for repair), and the mitral valve was sutured intermittently.
After examination of the valve location and the opening and closing performance of the valve leaf, the left atrial incision was sutured continuously by prolene 4/0.
Weaning from bypass start
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
identify of advantages and disadvantages of each approach
Time Frame: 1/1/2022 TO 1/1/2025
|
discussing and finding each approachs advantages and disadvantages and comparing with each other
|
1/1/2022 TO 1/1/2025
|
|
Assess the outcome regarding: -Wound size
Time Frame: 1/1/2022 TO 1/1/2025
|
measuring Wound size (in cm ) of each approach
|
1/1/2022 TO 1/1/2025
|
|
Assess the outcome regarding: -Postoperative pain and patient satisfaction
Time Frame: 1/1/2022 TO 1/1/2025
|
measuring postoperative pain and patient satisfaction by pain scale of each approach
|
1/1/2022 TO 1/1/2025
|
|
assess Wound complication
Time Frame: 1/1/2022 TO 1/1/2025
|
assess Wound complication (as infection (superfacial , deep , burst chest )
|
1/1/2022 TO 1/1/2025
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assess the outcome regarding: Economic factor
Time Frame: 1/1/2022 TO 1/1/2025
|
Assess the outcome regarding: -Economic factor ( ICU stay or hospital stay) |
1/1/2022 TO 1/1/2025
|
|
Assess the outcome regarding:Time of procedure
Time Frame: 1/1/2022 TO 1/1/2025
|
Assess the outcome regarding:Time of procedure ( time of total bypass time , time for rapid access, time of haemostasis)
|
1/1/2022 TO 1/1/2025
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Anwar A Atia, MD in cardiothoracic surgery, Professor of Cardiothoracic surgery
- Study Chair: Ahmed N Malik, MD in cardiothoracic surgery, Professor of Cardiothoracic surgery
Publications and helpful links
General Publications
- Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, Forouzanfar MH, Longenecker CT, Mayosi BM, Mensah GA, Nascimento BR, Ribeiro ALP, Sable CA, Steer AC, Naghavi M, Mokdad AH, Murray CJL, Vos T, Carapetis JR, Roth GA. Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015. N Engl J Med. 2017 Aug 24;377(8):713-722. doi: 10.1056/NEJMoa1603693.
- Antunes MJ. Minimally invasive valve surgery: reality, dream or utopia? J Heart Valve Dis. 1998 Jul;7(4):358-9. No abstract available.
- Takeda M, Konishi T, Fukata M, Matsuzaki K, Furuya K. [Minimally invasive surgery for single valvular heart disease]. J Cardiol. 1999 Oct;34(4):219-23. Japanese.
- Modi P, Hassan A, Chitwood WR Jr. Minimally invasive mitral valve surgery: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2008 Nov;34(5):943-52. doi: 10.1016/j.ejcts.2008.07.057. Epub 2008 Sep 30.
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- peri areolar MVR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.